(Q44640038)

English

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial

scientific article published on 30 October 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Patrick Verschueren

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

D De Cock

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

L Corluy

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

R Joos

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

C Langenaken

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

V Taelman

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

F Raeman

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

I Ravelingien

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

K Vandevyvere

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

J Lenaerts

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

E Geens

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

P Geusens

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

J Vanhoof

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

A Durnez

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

J Remans

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

B Vander Cruyssen

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

E Van Essche

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

A Sileghem

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

G De Brabanter

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

J Joly

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

S Meyfroidt

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

K Van der Elst

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

R Westhovens

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

0 references

publication date

30 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

74

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

27-34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Management of rheumatoid arthritis: summary of NICE guidance.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Optimal care for early RA patients: the challenge of translating scientific data into clinical practice

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Factors influencing the prescription of intensive combination treatment strategies for early rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 compariso

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Glucocorticoids

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2014-205489

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2014-205489

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25359382%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44640038&oldid=2030491112"